Omada Health Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2025
Omada Health (Nasdaq: OMDA) reported preliminary, unaudited revenue for Q4 2025 of $72M–$74M (up ~50%–54% YoY) and full-year 2025 revenue of $256M–$258M (up ~51%–52% YoY).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Omada Health (Nasdaq: OMDA) reported preliminary, unaudited revenue for Q4 2025 of $72M–$74M (up ~50%–54% YoY) and full-year 2025 revenue of $256M–$258M (up ~51%–52% YoY). Total members reached approximately 886,000 as of December 31, 2025, a 55% increase year-over-year. Results are preliminary and subject to completion of year-end closing procedures and the annual independent audit. Omada plans to release audited Q4 and FY2025 results on March 5, 2026 and will present at the J.P. Morgan Healthcare Conference on January 14, 2026.
Positive
- Preliminary full-year revenue $256M–$258M (+51%–52% YoY)
- Preliminary Q4 revenue $72M–$74M (+50%–54% YoY)
- Total members ~886,000 as of Dec 31, 2025 (+55% YoY)
- Company expanded GLP-1 care offerings and advanced AI on platform
Negative
- Revenue figures are preliminary and unaudited, subject to adjustment
- Audited results not available until March 5, 2026, creating timing uncertainty for investors
Details
News Market Reaction – OMDA
On Jan 12, the day this news came out, OMDA closed 4.61% above the previous close.
Data tracked by StockTitan Argus for the Jan 12 session.
Key Figures
- Q4 2025 revenue
- between $72 million and $74 million
- Preliminary, unaudited Q4 2025 revenue vs. Q4 2024
- Q4 revenue growth
- 50% to 54%
- Year-over-year growth vs. Q4 2024
- 2025 revenue
- between $256 million and $258 million
- Preliminary full-year 2025 revenue vs. 2024
- 2025 revenue growth
- 51% to 52%
- Full-year 2025 growth vs. 2024
- Total members
- approximately 886,000
- Members as of December 31, 2025; 55% year-over-year increase
- Member growth
- 55% year-over-year
- Member count growth to December 31, 2025
- Members served since launch
- more than one million
- Cumulative members served across programs
- Customer base
- 2,000+
- Employers, health plans, and health systems served
Historical Context
-
12‑month real‑world GLP-1 analysis showing strong, durable weight loss.
-
Announcement of presentation at the 44th Annual J.P. Morgan Healthcare Conference.
-
Notice of participation and fireside chat at Evercore Healthcare Conference.
-
Q3 2025 results with 49% revenue growth and first positive adjusted EBITDA.
-
Nationwide GLP-1 prescribing capability added to weight program offering.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
glp-1 medical
ai technical
forward-looking statements regulatory
u.s. private securities litigation reform act of 1995 regulatory
securities and exchange commission regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced preliminary, unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
Preliminary, unaudited revenue for the fourth quarter of 2025 is expected to be between
Omada also announced that total members reached approximately 886,000 as of December 31, 2025, an increase of
The unaudited results in this press release are preliminary and subject to the completion of Omada’s final closing procedures and annual independent audit and are subject to adjustment.
“Our preliminary 2025 results underscore the growing relevance of our between-visit care model as both buyers and members seek new solutions,” said Sean Duffy, Omada’s Co-founder and CEO. “During the year, we enhanced our GLP-1 care offerings and advanced the use of AI across our platform with an aim to drive sustainable member outcomes and support customers navigating evolving cost and care dynamics.”
Omada expects to report its audited fourth quarter and fiscal year 2025 results on March 5, 2026, after the close of market. Details for the conference call and webcast will be announced at a later date.
About Omada Health
Omada Health (Nasdaq: OMDA) is on a mission to fix what’s broken in chronic care. Today's healthcare system poorly serves chronic conditions that require ongoing support between doctor visits, like obesity, diabetes, hypertension, and musculoskeletal disorders. Omada’s virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada has served more than one million members since launch across 2,000+ employers, health plans, and health systems. Learn more at omadahealth.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements contained in this press release include, but are not limited to, statements we make regarding future financial and operating results, and our financial outlook.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, macroeconomic and industry conditions and other factors. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, but are not limited to, the following: our limited operating history and ability to manage our growth effectively; our history of net losses and ability to achieve or maintain profitability; the ability of our programs to achieve and maintain market acceptance; changes in the healthcare industry and competition; the growth and success of our customers and channel partners; the number of individuals covered by our programs and the number of our programs covered by our customers; the level of member engagement in our programs; our ability to maintain and grow customer and channel partner relationships; concentration of a substantial portion of our sales among a limited number of customers and channel partners; our ability to attract new customers and channel partners and increase member enrollment from existing and new customers and channel partners; our ability to increase the size of our organization; our dependence on a limited number of third-party suppliers; the impact of seasonality on our financial results; our ability to achieve widespread brand awareness and the impact of any negative media coverage; our ability to develop and release new programs and services; cybersecurity threats; our dependence on the interoperability of our programs and connected devices with third-party devices, operating systems and applications; changes in laws or regulations or the implementation of existing laws and regulations; compliance with privacy and security laws and regulations; our and our affiliated professional entities’ compliance with healthcare regulatory laws; any modification in U.S. Food and Drug Administration enforcement policies; our dependence on our relationships with affiliated professional entities; and other risk factors identified in our filings with the Securities and Exchange Commission (the “SEC”), including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
All forward-looking statements in this press release are based only on information currently available to us and speak only as of the date on which they are made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required under applicable law.
Investor Relations Contact
Allan Kells
ir@omadahealth.com
Media Contact:
Rose Ramseth
press@omadahealth.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.